PD-1/PD-L1抑制剂在外周T细胞淋巴瘤治疗中的研究进展

Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas

外周T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)是一组高度异质性和侵袭性的非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)。在目前化疗为主的治疗下,PTCL患者通常预后差,复发率高,因此需要积极探索新药来改善预后。肿瘤微环境(tumor microenvironment,TME)在多种肿瘤中发挥重要作用,程序性死亡[蛋白]-1(programmed death-1,PD-1)/程序性死亡[蛋白]配体-1(programmed death ligand-1,PD-L1)信号通路是参与肿瘤免疫逃逸的重要途径之一,针对PD-1/PD-L1通路的抑制剂在多种肿瘤中疗效显著,在PTCL的治疗上也有广阔的应用前景。研究表明在PTCL多种亚型中均有不同程度PD-1/PD-L1的表达,且PD-1单抗在部分亚型中疗效显著。现就PD-1/PD-L1在PTCL中的表达情况和其抑制剂的治疗进展作一综述。

Peripheral T-cell lymphomas(PTCLs)are a group of highly heterogeneous and aggressive non-Hodgkin’s lymphoma(NHL).PTCL patients have poor prognosis and high rates of relapse under the current chemotherapy-based treatment.Therefore,new drugs should be developed to improve the prognosis of PTCL.Tumor microenvironment(TME)plays an important role in many tumors.Programmed death-1(PD-1)/programmed death ligand-1(PD-L1)signaling pathway is one of the most important pathways involved in tumor immune escape.Inhibitors of the PD-1/PD-L1 pathway have exhibited remarkable effects in the treatment of multiple tumors and have broad application prospects in PTCL.Studies have found varying degrees of expressions of PD-1 and its ligands in multiple PTCL subtypes,and the PD-1 inhibitor has significant efficacy in some subtypes.In this paper,we reviewed the expression of PD-1/PD-L1 in PTCL and the therapeutic role of its inhibitors.